Skip to content Skip to footer
  • Index
  • Introduction
  • Situation
  • Solution
  • Technology
  • Results
  • A look to the future
Site Search Site Search
Featured insights Capabilities Industries Technology About us Careers

More

Featured insightsCapabilitiesIndustriesTechnologyAbout usCareers
My Account Sign Out
Sign in Register
Global

AlbaniaAmericaAndorraAngolaArgentinaArmeniaAustraliaAustriaAzerbaijanBahamasBahrainBarbadosBelgiumBermudaBoliviaBosnia and HerzegovinaBotswanaBrasilBritish Virgin IslandsBruneiBulgariaCambodiaCanadaCape VerdeCaribbeanCayman IslandsCentral and Eastern EuropeChannel IslandsChileChinaColombiaCosta RicaCroatiaCyprusCzech RepublicDenmarkDominican RepublicEcuadorEgyptEl SalvadorEstoniaFinlandFranceGazaGeorgiaGermanyGhanaGibraltarGreeceGuatemalaHondurasHong Kong SAR, ChinaHungaryIcelandIndiaIndonesiaInteraméricasIraqIreland (Republic of)Isle of ManIsraelItalyJamaicaJapanJordanKazakhstanKenyaKosovoKuwaitLaosLatviaLebanonLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacedoniaMalaysiaMaltaMauritiusMexicoMiddle East RegionMoldovaMongoliaMontenegroMozambiqueMéxicoNamibiaNetherlandsNetherlands AntillesNew ZealandNicaraguaNigeriaNorwayOmanPakistanPanamaPapua New GuineaParaguayPeruPhilippinesPolandPortugalQatarRomaniaRwandaSaudi ArabiaSerbiaSingaporeSlovakiaSloveniaSouth AfricaSouth KoreaSpainSwedenSwitzerlandTaiwanTanzaniaThailandTrinidad and TobagoTurkeyTürkiyeU.S.UKUSUSAUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVenezuela VietnamWest BankZambiaeSwatini/SwazilandУкраїнаישראל中国臺灣
Home Research and insights Case studies OSIC healthcare technology case study: PwC

Menu

Featured insights
Featured insights
2025 Global Digital Trust Insights Survey Board governance issues C-suite insights Case studies ESG Policy on Demand Podcasts PwC Executive Pulse Tech Effect Webcasts All Research and insights

Menu

Featured insights
2025 Global Digital Trust Insights Survey

Menu

Featured insights
Board governance issues

Menu

Featured insights
C-suite insights
Board of directors Chief Executive Officer (CEO) Chief Financial Officer (CFO) Chief Information Officer (CIO) Chief Information Security Officer (CISO) Chief Marketing Officer (CMO) Chief Operating Officer (COO) Chief Risk Officer (CRO) Controller Corporate development Future CFO Legal officer Sustainability leader Tax leader Transformation leader

Menu

Featured insights
Case studies

Menu

Featured insights
ESG

Menu

Featured insights
Policy on Demand

Menu

Featured insights
Podcasts

Menu

Featured insights
PwC Executive Pulse

Menu

Featured insights
Tech Effect

Menu

Featured insights
Webcasts

Menu

Featured insights
All Research and insights

Featured

America in motion

Executive leadership hub - What’s important to the C-suite?

Menu

Capabilities
Capabilities
Audit and Assurance Alliances and ecosystems Artificial Intelligence (AI) Board governance issues Business model reinvention Consulting Cybersecurity, Risk and Regulatory Deals Digital assets and crypto Digital assurance and transparency Financial Markets & Real Estate Financial statement audit Managed Services Metaverse PwC Private Risk Modeling Services Sustainability and ESG Tax services Technology and transformation Viewpoint All capabilities

Menu

Capabilities
Audit and Assurance

Menu

Capabilities
Alliances and ecosystems
Adobe Amazon Web Services Google Guidewire Microsoft Oracle Salesforce SAP Workday All alliances

Menu

Capabilities
Artificial Intelligence (AI)

Menu

Capabilities
Board governance issues

Menu

Capabilities
Business model reinvention

Menu

Capabilities
Consulting

Menu

Capabilities
Cybersecurity, Risk and Regulatory
Cybersecurity defense and engineering Data risk and privacy Investigations and forensics Strategy, risk and compliance Enterprise risk and controls solutions Enterprise tech solutions Financial crimes Risk and regulatory - Financial services Risk and regulatory - Health industries

Menu

Capabilities
Deals
Acquisitions Capital markets Deals strategy Divestitures JVs and strategic alliances M&A integration M&A technology Portfolio company value creation Turnaround and restructuring

Menu

Capabilities
Digital assets and crypto

Menu

Capabilities
Digital assurance and transparency

Menu

Capabilities
Financial Markets & Real Estate

Menu

Capabilities
Financial statement audit

Menu

Capabilities
Managed Services
Business Outcome Managed Services Risk and Regulatory Managed Services Technology Managed Services

Menu

Capabilities
Metaverse

Menu

Capabilities
PwC Private
Family enterprises Law firms Private equity and portfolio companies Ultra high net worth individuals US inbounds

Menu

Capabilities
Risk Modeling Services

Menu

Capabilities
Sustainability and ESG
ESG reporting Sustainability strategy Sustainable technology and digital

Menu

Capabilities
Tax services

Menu

Capabilities
Technology and transformation
Alliances and Ecosystems Application Evolution Managed Services Cloud engineering Cloud transformation Customer transformation Data and analytics Enterprise strategy and value Experience Center Finance transformation Industry cloud Operations transformation Technology strategy Workforce transformation

Menu

Capabilities
Viewpoint

Menu

Capabilities
All capabilities

Menu

Industries
Industries
Consumer markets Financial services Health industries Industrial products and services Technology, media and telecommunications All industries

Menu

Industries
Consumer markets
Consumer packaged goods Hospitality and leisure Restaurants, wholesale and agriculture Retail Travel, transportation and logistics

Menu

Industries
Financial services
Asset and wealth management Banking and capital markets Insurance Private Equity

Menu

Industries
Health industries
Emerging companies Health Research Institute Health services Medical technology Pharmaceuticals and life sciences

Menu

Industries
Industrial products and services
Aerospace and defense Automotive Capital projects and infrastructure Chemicals Energy Engineering and construction Forest, paper, and packaging Industrial manufacturing Metals Mining Power and utilities Space

Menu

Industries
Technology, media and telecommunications
Emerging companies Media Sports Technology Telecommunications

Menu

Industries
All industries

Menu

Technology
Technology
Alliances and ecosystems Delivery platforms Emerging technology Products Tech-enabled services Tech Effect Technology and Transformation

Menu

Technology
Alliances and ecosystems
Adobe Amazon Web Services Google Cloud Guidewire Microsoft Oracle Salesforce SAP Workday

Menu

Technology
Delivery platforms
Aura Concourse Sightline

Menu

Technology
Emerging technology
Artificial Intelligence (AI) Digital assets and crypto Metaverse Responsible AI Web3

Menu

Technology
Products
Analytics Foundation Beacon Bookkeeping Connect Connected Solutions Enterprise Control Investor Survey Model Edge Next Level HR Profit Seeker Ready Assess Saratoga Risk Link View all products

Menu

Technology
Tech-enabled services
Agile Commerce Carbon Ledger Culture Thumbprint Enhanced insurance analytics for Salesforce ESG Geospatial Climate Intelligence (GCI) Insights to Enablement Market Advantage Payer Advocacy Center Ready Command Shovel Ready

Menu

Technology
Tech Effect

Menu

Technology
Technology and Transformation
Alliances and Ecosystems Application Evolution Managed Services Cloud engineering Cloud transformation Customer transformation Data and analytics Enterprise strategy and value Experience Center Finance transformation Industry cloud Operations transformation Technology strategy Workforce transformation

Menu

About us
About us
Alumni Analyst relations Investing in our people Newsroom Offices Our leadership Purpose and values

Menu

About us
Alumni
Join the PwC Alumni Network Meet our alumni

Menu

About us
Analyst relations

Menu

About us
Investing in our people

Menu

About us
Newsroom

Menu

About us
Offices

Menu

About us
Our leadership

Menu

About us
Purpose and values
Be Well, Work Well Environmental sustainability Inclusion Social impact

Featured

Tech Effect

Menu

Careers
Careers
Why PwC Entry Level Careers Experienced Careers University Relations

Menu

Careers
Why PwC
Benefits & Compensation Our Culture The PwC Professional US Careers Podcast hub

Menu

Careers
Entry Level Careers
Advance Internship Military and Veterans Recruiting process Search opportunities Student Development Programs Student programs quiz

Menu

Careers
Experienced Careers
Alumni Careers Contract opportunities Military and Veterans Search opportunities

Menu

Careers
University Relations
Faculty Newsletter University Relations

Featured

Shared success benefits

Loading Results

No Match Found

A brighter future for

medicine with healthcare technology

Copy link Link copied to clipboard
  • CLIENT

    /content/dam/pwc/us/en/library/case-studies/assets/osic/osic-case-study-logo-sm.svg

  • INDUSTRY

    Healthcare Technology

  • OUR ROLE

    Illuminating the power of strategic thinking and technology in the fight against rare disease

  • FEATURING

    Microsoft Azure

A deadly, rare lung disease that affects hundreds of thousands of people worldwide

Idiopathic pulmonary fibrosis (IPF) has no known cause or cure—and it’s very difficult to diagnose.

2+ years

median time to diagnosis1


3-5 years

average life expectancy after diagnosis2

A first-of-its-kind open source medical imaging and data repository platform is highlighting new possibilities to help improve the speed and accuracy of diagnosis and help patients, providers and researchers better manage the disease.

OSIC’s commitment to highlighting rare disease, Microsoft’s secure and flexible technology and PwC’s dedication to solving important problems and building trust in society are together driving vital advancements in medicine that can change patient lives for the better.

15,000

scans projected to be included in the database by the end of 20223

“

We needed a groundbreaking database but didn’t have all the pieces in place. PwC was essential in helping to put it all together—securely and intentionally.

Elizabeth Estes
Executive Director, OSIC

The Open Source Imaging Consortium Data Repository, supported by PwC and Microsoft

A platform for sharing anonymized global imaging and clinical data that can impact diagnosis and decision-making, with the fundamental goal of better patient outcomes. 

Within months of launch, this groundbreaking effort is already promising to enable more timely, accurate diagnoses for IPF patients. In time, OSIC hopes to use AI technology to shine a spotlight on other rare diseases and help further democratize medicine, giving patients around the world the same diagnostic tools available to those in major research centers.

Situation

Shining a light
on rare disease

For patients navigating interstitial lung diseases (ILDs), seeing the big picture means the ability to make more informed decisions.

One key to diagnosing IPF and other ILDs lies in identifying a specific pattern on a chest scan via high-resolution computed tomography (HRCT).

But identifying patterns on a scan can be challenging. Rare diseases make for rare data, and medical providers are often left with only limited snapshots based on highly variable, siloed information. Creating a more complete picture of what patients face and decreasing the time to diagnosis are two of the more impactful ways to improve outcomes for those with IPF.

Current clinical challenges of IPF

  • Interpretations of imaging are subject to significant variability between observers.
  • Specialists don’t always have a holistic understanding of staging or disease progression.
  • There are no tools to predict the disease’s progression in individual patients.
  • Even with a diagnosis, patients are subject to a variable clinical course.

“

OSIC and Microsoft have shown how powerful technology can be for healthcare, opening doors in care, research and delivery.

Will Perry
US Cloud Innovation & Engineering Leader, PwC

Solution

Connecting patients, providers and a central consortium

OSIC is a 501(c)(3) not-for-profit cooperative effort that brings together members from academia, industry and patient advocacy groups. This groundbreaking coalition has turned sometimes-competitors into willing collaborators, leveraging their collective knowledge to help accelerate the fight against IPF, fibrosing ILDs and other respiratory diseases including emphysematous conditions.

The real story of OSIC is how it impacts the lives of patients

By coalescing critical research, experience and clinical data into one central repository, OSIC looks to enable more accurate imaging-based prognosis, diagnosis and prediction of response to therapy. Doctors and researchers can now be connected with the resources and experience they need for improved patient care.

A connected relationship

Clinicians and researchers provide their institution’s high-quality, anonymized HRCT scans with accompanying clinical data to a large database. They can then access this same database to find data from other participants, which they can then use to build predictive models and change lives.

The consortium provides members with access to the data-rich repository, which houses a plethora of multi-ethnic and multi-center, real-world clinical and imaging data. The database is managed in compliance with applicable privacy laws, regulations, consents and related restrictions.

Patients receive more targeted treatment decisions, ultimately leading to earlier diagnosis, enhanced prognosis and improved management of disease.

Powering diagnostics with Microsoft technology

Using Microsoft Azure, PwC collaboratively constructed a data repository to house all of OSIC’s anonymized images and clinical data. The platform looks to incorporate a crowdsourced algorithm that detects IPF progression.

PwC helped design the platform and, together with OSIC-member expertise, led the intake and management process for diagnostic imaging data and performed both manual and automated data quality checks. In the future, these checks can help enable a highly secure AI, machine learning and sightless diagnostic environment to accelerate rare disease treatment.

1. Security

Anonymized data is encrypted, transferred and stored in a secure, digital vault that’s monitored continuously to prevent public access.

2. Intake

The platform performs automated, multi-stage quality control and anonymization of metadata before ingesting images and data sets.

3. Data access

Members can leverage scans and rich data sets collaboratively for imaging-based diagnosis, prognosis and prediction of response to therapy.​​

4. AI and machine learning

Thousands of scans look to supplement provider observations with principled AI and machine learning to determine whether an HRCT scan shows early signs of IPF.

5. Detection, treatment and time

Providers aspire to deliver faster, more accurate diagnoses and predictions to give patients more time under treatment.

“

OSIC’s contribution to the healthcare industry is the true definition of innovation. This collaboration demonstrates our mission of empowering others to achieve more.

Patricia Obermaier
Vice President, US Health and Life Sciences, Microsoft
Results

Improving patient experiences and health outcomes

A data-powered solution is not successful until people can understand and use it. The OSIC Data Repository is designed to dramatically increase the volume and usability of vital information to fuel faster decisions and predict better treatment outcomes.

More diverse data

The medical community was relying on limited information, such as scans from a center’s own region or missing data from referral sites, to illustrate how the disease might progress. And because IPF is a rare disease, no single center had enough patients to supply the data needed for real progress. The OSIC Data Repository’s large database could help healthcare professionals build algorithms to find answers and change lives.

Worldwide connectivity

The OSIC Data Repository pulls together a plethora of global, multi-ethnic clinical and imaging data that can help cut down the time to diagnosis.

Democratizing medicine

OSIC clinicians and research members in any location would have access to and benefit from the same technology and information as those affiliated with major research centers. Any OSIC-created algorithms will be made open source for the benefit of patients everywhere.

Continuous improvement

The platform is designed to explain the patterns detected by its AI so providers could then apply their own insights and learn alongside the AI.

By the numbers



+

patient cases



+

patients with follow-up data



anticipated scans by end of 2022

“

Being able to reliably predict how pulmonary fibrosis will progress…would allow doctors to initiate appropriate treatment at the earliest opportunity and slow disease progression.

Dr. Simon Walsh

National Heart and Lung Institute, ​Imperial College London, OSIC Radiology Lead, "Why the OSIC Data Repository Matters"

 

Lighting

 the way forward

The OSIC model looks to yield far-reaching benefits for IPF and beyond

The impressive early feedback has OSIC thinking big. Its model represents a beacon of hope for those fighting pulmonary fibrosis and other rare lung diseases.

Digital biomarkers

Successful outcomes through OSIC could result in open source digital biomarkers that support reliable and accurate diagnosis and prediction of outcome in patients with IPF and other progressive fibrosing respiratory disorders.

New uses for old imaging

HRCTs aren’t available everywhere, but the OSIC platform could make better use of more widely available X-ray technology by associating patient X-rays with their CT-based diagnosis. In time, the platform could expand to different modalities, including X-rays.

Applications for other rare diseases

The OSIC platform is very flexible, and its AI can push the limits of medical diagnoses and prediction of outcome. As the OSIC database expands and adds more contributors, it’s likely to help shine a light on other rare diseases, providing much-needed research and attention.

1. "Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry," US National Library of Medicine, BMJ Open Respiratory Research, July 5, 2020.
2. Emily Malcolm, "12 Facts About Pulmonary Fibrosis Prognosis and Life Expectancy," Pulmonary Fibrosis News, August 16, 2019.
3. Open Source Imaging Consortium
4. "September is Pulmonary Fibrosis Month," American Association for Respiratory Care, August 27, 2021.
5. "September is Pulmonary Fibrosis Month," American Association for Respiratory Care, August 27, 2021.
6. "Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY study," US National Library of Medicine, BMC Pulmonary Medicine, January 17, 2018.

Explore PwC's case study library

explore

Share this case study

Related content

Wired article: A Bold Approach to Rare Disease

Improving patient treatment and care through data transparency with OSIC, PwC and Microsoft.

Contact us

Will Perry

Principal, PwC US

Linkedin Follow Email
Hide

Thank you for your interest in PwC

We have received your information. Should you need to refer back to this submission in the future, please use reference number "refID".

Required fields are marked with an asterisk(*)

Please correct the errors and send your information again.

By submitting your email address, you acknowledge that you have read the Privacy Statement and that you consent to our processing data in accordance with the Privacy Statement (including international transfers). If you change your mind at any time about wishing to receive the information from us, you can send us an email message using the Contact Us page.

Audit and Assurance services Consulting Tax services Newsroom Alumni US offices Contact us

© 2017 - 2025 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.

  • Privacy
  • Data Privacy Framework
  • Cookie info
  • Legal
  • Terms and conditions
  • Site provider
  • Site map
  • Your Privacy Choices